相关实验视频

Updated: Jul 1, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

在肺动脉高血压中风险分层方面,REVEAL Lite 2和COMPERA 2.0之间的比较

Sandeep Sahay¹, Nelson Villasmil Hernandez², Fredrick Wang³

¹Division of Pulmonary, Critical Care & Sleep Medicine, Houston Methodist Hospital, Houston, TX.

|March 6, 2024

概括

与COMPERA模型相比,REVEAL Lite 2风险评分显示了肺动脉高血压 (PAH) 患者的基线风险歧视优越. 这表明REVEAL Lite 2可能会改善PAH管理中的临床决策.

科学领域:

心脏病学心脏病学
肺部病理学肺部病理学
医疗信息学医疗信息学

背景情况:

肺动脉高血压 (PAH) 的管理依赖于风险分层.
目前的指导方针建议使用COMPERA (肺高血压新启动疗法的比较,前性注册) 风险模型.
现有的指南不包括REVEAL Lite 2风险评分.

研究的目的:

将REVEAL Lite 2的风险歧视性能与COMPERA风险评估模型进行比较.
在PAH患者的基线和随访时评估模型.
为了确定REVEAL Lite 2是否提供了更好的预后准确性.

主要方法:

来自单一专家中心注册的PAH患者数据的分析 (2011年6月至2022年2月).
使用REVEAL Lite 2和COMPERA (3层和4层) 风险评分的患者的分层.
使用ROC曲线和哈雷尔C统计数据预测肺移植或死亡.

主要成果:

与COMPERA3层 (0.63) 和4层 (0.68) 模型相比,REVEAL Lite 2在基线显示出更高的C统计值 (0.74).
在REVEAL Lite 2和COMPERA模型之间的所有基线C统计差异中观察到统计显著性.
一,三,五,七年的无移植生存率分别为93.6%,81.3%,75.1%和68.8%.

结论:

在研究的PAH队列中,REVEAL Lite 2表现出优越的基线风险歧视.
建议将REVEAL Lite 2纳入未来的指南,以改善临床决策.
需要在更大的患者队伍中进一步验证,以证实这些发现.

关键词:

康佩拉 (Compera) 是一个城市.在 COMPERA 2.0 中,使用的是 COMPERA 2.0.这就是REVEAL Lite 2的原因.有四层层的肺动脉高血压肺动脉高血压风险是歧视的风险.风险评分风险评分是什么意思风险分层的风险分层.幸存率幸存率生存率有三层的层.

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Relative Risk

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...